SFJ XI (Apellis)

SFJ and Apellis Pharmaceuticals (Nasdaq: APPL) are collaborating on the development of APL-2, a novel therapeutic targeting complement, in haematologic indications including Paroxysmal Nocturnal Haemoglobinuria (PNH).